Study guide
9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections
Key Takeaways Explain This Topic AI
The UK Medical Eligibility Criteria (UKMEC) categorizes contraceptive safety from UKMEC 1 (unrestricted) to UKMEC 4 (unacceptable health risk); Combined Hormonal Contraception (CHC) is UKMEC 4 in migraine with aura, smoking ≥15 cigarettes/day at age ≥35, severe hypertension (≥160/100 mmHg), and personal history of VTE.
For standard 21-day monophasic COCPs, missing 1 pill (<48h since last dose) requires taking the missed pill immediately with no additional barrier precautions; missing 2 or more pills (≥48h late) requires taking the most recent pill, using condoms for 7 days, and omitting the pill-free break if pills are missed in Week 3.
Emergency contraception modalities include the Copper IUD (>99% effective up to 120h post-UPSI, unaffected by BMI), Ulipristal acetate (ellaOne, up to 120h; requires a 5-day pause before starting hormonal contraception plus 12 days total barrier use), and Levonorgestrel (Levonelle, up to 72h; double dose to 3 mg if BMI >26 kg/m² or taking enzyme inducers).
Sexually transmitted infection treatment guidelines mandate oral doxycycline 100 mg BD for 7 days for Chlamydia trachomatis, single-dose IM ceftriaxone 1 g stat for Neisseria gonorrhoeae, and IM benzathine penicillin G for Treponema pallidum (syphilis).
HIV Post-Exposure Prophylaxis (PEP) is time-critical and must be initiated within 72 hours of potential exposure (optimally <24h) and continued as a 28-day course of triple antiretroviral therapy.
Last updated: October 2026
Contraception, Emergency Contraception & Sexually Transmitted Infections
Contraceptive counselling, emergency pregnancy prevention, and genitourinary medicine form core components of women's and sexual health in UK clinical practice. Clinicians must apply the UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) to ensure safe prescribing and execute time-critical interventions for emergency contraception and sexually transmitted infections (STIs).
UK Medical Eligibility Criteria (UKMEC) & Combined Hormonal Contraception
The Faculty of Sexual and Reproductive Healthcare (FSRH) defines four UKMEC categories to guide prescribing safety:
UKMEC 1: A condition for which there is no restriction for the use of the contraceptive method.
UKMEC 2: A condition where the advantages of using the method generally outweigh the theoretical or proven risks .
UKMEC 3: A condition where the theoretical or proven risks usually outweigh the advantages of using the method (specialist consultation required; method not recommended unless other options unavailable or declined).
UKMEC 4: A condition that represents an unacceptable health risk (absolute contraindication; the method must NOT be used).
Combined Hormonal Contraception (CHC: COCP, Transdermal Patch, Vaginal Ring)
Combined hormonal methods contain both an oestrogen (ethinylestradiol or estradiol) and a progestogen. Oestrogen promotes hepatic production of clotting factors (fibrinogen, factors VII, VIII, X) and suppresses antithrombin III, increasing thromboembolic and cardiovascular risk.
Clinical Condition / Risk Factor UKMEC Category for Combined Hormonal Contraception (CHC) Clinical Rationale & Safe Alternatives
Migraine WITH Aura (at any age) UKMEC 4 (Absolute Contraindication) Dramatic synergistic elevation in ischaemic stroke risk . Progestogen-only pill (POP), implant (Nexplanon), or LNG-IUS are UKMEC 1/2
Age ≥ 35 years smoking ≥ 15 cigarettes/day UKMEC 4 (Absolute Contraindication) Exponential increase in arterial thrombosis, myocardial infarction, and stroke. (Smoking < 15 cigarettes/day at age ≥ 35 is UKMEC 3)
Uncontrolled Severe Hypertension (Systolic ≥ 160 or Diastolic ≥ 100 mmHg) UKMEC 4 (Absolute Contraindication) Massive cardiovascular strain and stroke risk. (Controlled hypertension or BP 140–159/90–99 mmHg is UKMEC 3)
Personal History of VTE / Pulmonary Embolism or known thrombogenic mutation UKMEC 4 (Absolute Contraindication) High recurrence rate of venous thromboembolism. Progestogen-only methods or non-hormonal Copper IUD are safe
Current Breast Cancer (past breast cancer with no evidence of disease for 5 years is UKMEC 3) UKMEC 4 (Contraindication to all hormonal methods) Hormone-receptor-positive tumor proliferation. Copper IUD is the only completely safe method (UKMEC 1)
Ischaemic Heart Disease / Stroke / TIA UKMEC 4 (Absolute Contraindication) High risk of recurrent arterial vascular events
Diabetes with End-Organ Complications (retinopathy, nephropathy, neuropathy) or > 20 years duration UKMEC 3 / 4 Severe microvascular compromise
- Body Mass Index (BMI) ≥ 35 kg/m² UKMEC 3 Substantially elevated baseline VTE risk (BMI 30–34 kg/m² is UKMEC 2)
- Missed Pill Rules & Patient Guidance
- Standard 21-Day Monophasic Combined Oral Contraceptive (COCP)
A pill is considered "missed" if taken more than 24 hours late (i.e., more than 48 hours since the last pill was ingested).
ONE Pill Missed (24–48 hours late):
Action: Take the delayed/missed pill immediately (even if this means taking two pills in one day), then continue the remaining pills at the usual time.
Extra Precautions: No additional barrier contraception is required ; contraceptive efficacy is maintained.
TWO OR MORE Pills Missed (≥ 48 hours late):
Action: Take the most recently missed pill immediately; discard any earlier missed pills. Continue taking subsequent pills at the regular daily time.
Extra Precautions: Use condoms (or abstain) for the next 7 consecutive days .
Critical Timing Rules:
Missed in Week 1 (Days 1–7): If unprotected sexual intercourse (UPSI) occurred during the 7-day pill-free break or during Week 1, emergency contraception is indicated .
Missed in Week 2 (Days 8–14): If the 7 pills preceding the missed pills were taken correctly, no emergency contraception is needed; maintain condoms for 7 days.
Missed in Week 3 (Days 15–21): Finish the current active pack and OMIT the upcoming 7-day pill-free interval , starting the next pack immediately the following day.
Progestogen-Only Pill (POP)
Traditional POP (Levonorgestrel / Norethisterone): 3-hour missed pill window.
Desogestrel POP (Cerazette 75 mcg): 12-hour missed pill window (inhibits ovulation in >97% of cycles).
Drospirenone POP (Slynd): 24-hour missed pill window.
Action when POP is Missed Beyond the Window: Take the missed pill immediately, continue the pack, and use barrier contraception (condoms) for 48 hours (2 days) . If UPSI occurred after the missed pill before 48 hours of compliant use has elapsed, emergency contraception is required.
Long-Acting Reversible Contraception (LARC)
LARC methods have the highest real-world efficacy because they are independent of user compliance:
Copper Intrauterine Device (Cu-IUD): Non-hormonal device releasing copper ions that impair sperm motility and induce local sterile inflammatory endometrial changes preventing blastocyst implantation. Duration: 5 to 10 years . May cause heavier, more painful menses.
Levonorgestrel Intrauterine System (52 mg LNG-IUS / Mirena): Locally releases levonorgestrel to induce profound endometrial atrophy, thickening of cervical mucus, and variable anovulation. Duration: 5 to 8 years . Dramatic reduction in menstrual blood loss (>80% develop oligomenorrhoea or amenorrhoea).
Progestogen Subdermal Implant (Nexplanon): Single rod containing 68 mg etonogestrel inserted into the upper inner arm. Duration: 3 years . High efficacy; primary side effect is unpredictable irregular spotting or prolonged amenorrhoea.
Depot Medroxyprogesterone Acetate (DMPA / Depo-Provera): Intramuscular injection (150 mg) repeated every 13 weeks (FSRH: can be given up to 14 weeks without extra precautions). Delays return of fertility by up to 12 months after discontinuation; associated with transient reduction in bone mineral density (requires clinical review every 2 years).
Emergency Contraception (EC)
Three emergency contraceptive modalities are available in the UK, each with distinct mechanisms, windows of efficacy, and drug interactions:
Modality Window of Efficacy Efficacy Rate & BMI Impact Interactions & Restarting Hormonal Contraception
Copper Intrauterine Device (Cu-IUD) Up to 120 hours (5 days) after UPSI, OR up to 5 days after the earliest calculated date of ovulation > 99% effective (Gold Standard). Efficacy is completely unaffected by BMI or enzyme-inducing drugs Provides immediate, ongoing long-term contraception. Unrestricted by previous oral emergency pill intake
Ulipristal Acetate (ellaOne 30 mg oral stat) Up to 120 hours (5 days) post-UPSI Highly effective; delays LH surge even after LH levels begin to rise. Efficacy is reduced if BMI > 30 kg/m² or weight > 85 kg Hormonal Contraception Interference: Exogenous progestogens displace ulipristal from receptors. Patient must WAIT 5 DAYS before starting/resuming hormonal contraception , and use condoms for 5 days + 7 days = 12 days total (14 days for Qlaira; 7 days for the POP). Not recommended in severe asthma controlled by oral corticosteroids
Levonorgestrel (Levonelle 1.5 mg oral stat) Up to 72 hours (3 days) post-UPSI Effective before LH surge begins. Ineffective once LH surge is underway. Efficacy reduced if BMI > 26 kg/m² or weight > 70 kg Double Dose (3 mg stat) required if BMI > 26 kg/m², weight > 70 kg, or taking cytochrome P450 enzyme inducers. Hormonal contraception can be quick-started immediately ; condoms required for 7 days (2 days for POP)
- Sexually Transmitted Infections (STIs) & Prophylaxis
- 1. Chlamydia trachomatis
Presentation: Most common bacterial STI in the UK. Up to 80% of women and 50% of men are asymptomatic. Symptoms include abnormal vaginal discharge, dysuria, intermenstrual bleeding, or post-coital bleeding; in men, urethral discharge and dysuria. Complications include PID, ectopic pregnancy, tubal factor subfertility, and epididymo-orchitis.
Diagnosis: First-catch urine in men; vulvovaginal swab for Nucleic Acid Amplification Testing (NAAT) in women.
Treatment (BASHH):
First-line: Oral Doxycycline 100 mg twice daily for 7 days .
Second-line / Pregnancy / Allergy: Oral Azithromycin 1 g stat followed by 500 mg daily for 2 days, or oral Amoxicillin 500 mg TDS for 7 days, or Erythromycin 500 mg QDS for 7 days.
2. Neisseria gonorrhoeae
Presentation: Gram-negative intracellular diplococci. Causes copious purulent urethral or vaginal discharge, dysuria, and pelvic pain. High resistance rates to penicillins, ciprofloxacin, and azithromycin.
Diagnosis: Endocervical / vulvovaginal or first-catch urine NAAT plus culture and antimicrobial susceptibility testing.
Treatment (BASHH): Intramuscular Ceftriaxone 1 g stat (single IM injection diluted in 1% lidocaine). Monotherapy is standard following revised resistance guidance.
3. Syphilis (Treponema pallidum)
Primary Syphilis: Single, indurated, painless ulcer (hard chancre) with a clean base and raised rolled borders, accompanied by painless non-suppurative regional lymphadenopathy. Develops 2–3 weeks after exposure and heals spontaneously in 3–8 weeks.
Secondary Syphilis (6–12 weeks later): Systemic haematogenous dissemination: non-pruritic maculopapular rash characteristically involving the palms of the hands and soles of the feet , condylomata lata (flat, moist, highly infectious wart-like lesions in genital skin folds), generalized lymphadenopathy, snail-track oral ulcers, and patchy alopecia.
Tertiary Syphilis (years later): Gummas (granulomatous destructive lesions of skin/bone), cardiovascular syphilis (ascending aortic aneurysms, aortic regurgitation), and neurosyphilis (tabes dorsalis, Argyll Robertson pupils, dementia).
Diagnosis: Dark-field microscopy or treponemal PCR of ulcer exudate. Serology: Treponemal tests (TPHA, TPPA, EIA; remain positive for life) confirm infection; non-treponemal tests (VDRL, RPR) reflect disease activity and monitor response to therapy.
Treatment: Intramuscular Benzathine Penicillin G 2.4 million units stat (single IM dose for primary, secondary, and early latent syphilis; given weekly for 3 weeks in late latent syphilis). Doxycycline 100 mg BD for 14 days is used for penicillin-allergic patients. Patients must be warned about the Jarisch-Herxheimer reaction (acute febrile episode with chills and myalgia occurring within 24 hours of first penicillin dose).
4. HIV Post-Exposure Prophylaxis (PEP / PEPSE)
Indicated following significant sexual or occupational exposure to body fluids from an individual known or suspected to be HIV-positive with a detectable viral load.
Time Window: Must be commenced within 72 hours of exposure (greatest efficacy when initiated within 24 hours; ineffective after 72 hours).
Regimen: A 28-day course of triple antiretroviral therapy (e.g., Tenofovir disoproxil + Emtricitabine [Truvada] once daily PLUS Raltegravir 1200 mg once daily or Dolutegravir 50 mg once daily).
Baseline and 4–6 week follow-up HIV serology and renal profile monitoring are mandatory.
Trichomoniasis
Trichomonas vaginalis is a sexually transmitted protozoan causing frothy yellow-green offensive vaginal discharge , vulval itching and soreness, and sometimes a " strawberry cervix "; men are often asymptomatic or have urethritis. Diagnose with a NAAT (or microscopy) on a vaginal swab. Treat with metronidazole (for example 400–500 mg twice daily for 7 days, per BASHH), advise avoiding sex until treatment of both partners is complete, and arrange partner notification and screening for other STIs.